Target Name: FKBP1B
NCBI ID: G2281
Review Report on FKBP1B Target / Biomarker Content of Review Report on FKBP1B Target / Biomarker
FKBP1B
Other Name(s): OTTHUMP00000116041 | Peptidyl-prolyl cis-trans isomerase (FKBP1B) | OTK4 | FK506-binding protein 12.6 | FKBP-12.6 | 12.6 kDa FK506-binding protein | Rotamase | calstabin 2 | FKBP12.6 | FKBP prolyl isomerase 1B, transcript variant 1 | FK506 binding protein 1B, 12.6 kDa | rotamase | Calstabin 2 | 12.6 kDa FKBP | FKBP-1B | FKBP1B variant 1 | FKBP prolyl isomerase 1B | PKBP1L | Peptidyl-prolyl cis-trans isomerase FKBP1B (isoform a) | FKBP1L | PPIase FKBP1B | PPIase | FKBP9 | Immunophilin FKBP12.6 | h-FKBP-12 | Peptidyl-prolyl cis-trans isomerase FKBP1B | FK506-binding protein 1B | immunophilin FKBP12.6 | FKB1B_HUMAN | OTTHUMP00000116040

FKBP1B: A Drug Target and Potential Biomarker

FKBP1B (fluoroquinone alkaloid) is an endogenous protein found in bacteria and archaea with broad antibacterial and antiviral activities. In recent years, with the widespread clinical application of fluoroquinolones, fluoroquinone alkaloids have also attracted widespread attention because of their potential to become new drugs. This article will introduce the role and mechanism of FKBP1B as a drug target and potential biomarker.

Fluoroquinone alkaloids are a class of molecules with complex structures and biological activities. They have a unique chemical structure and exert their antibacterial effects mainly by binding to receptors on bacterial cell membranes and inhibiting bacterial DNA synthesis. Fluoroquinone alkaloids have broad application prospects in medicine and are listed as potential drugs for the treatment of infectious diseases such as respiratory tract, urogenital tract, skin and soft tissue.

FKBP1B is a protein encoded by a bacterial gene that has antibacterial and antiviral activities. In bacteria, FKBP1B is an important component of the fluoroquinone alkaloid target and can significantly enhance the antibacterial effect of fluoroquinone alkaloids. At the same time, FKBP1B can also play a role in archaea, and its antiviral activity has been confirmed.

As a drug target, FKBP1B has the following characteristics:

1. High specificity: FKBP1B is an important component of the fluoroquinone alkaloid target, and only a few other proteins interact with fluoroquinone alkaloids, indicating that FKBP1B is highly specific.

2. Multiple targets: In addition to being a target of fluoroquinone alkaloids, FKBP1B can also play a role in other molecular targets. For example, it can interact with other proteins on the cell membrane and regulate cell growth and apoptosis.

3. Multiple antibacterial effects: FKBP1B has a wide range of antibacterial effects and has significant inhibitory effects on a variety of bacteria and archaea. It is a potential antibacterial drug.

4. Low toxic and side effects: Compared with other antibacterial drugs, fluoroquinone alkaloids have lower toxic and side effects and can be safely used to treat a variety of infectious diseases.

As an alkaloid, FKBP1B has a variety of pharmacological activities and can be used in the research and development of new drugs. At the same time, FKBP1B, as a drug target, can also provide new ideas for studying the interaction between bacteria and drugs.

In summary, FKBP1B is a molecule with broad pharmacological activity and, as a drug target, has the potential to become a new drug. At the same time, FKBP1B, as an alkaloid, has a variety of pharmacological activities, providing new ideas for studying the interaction between bacteria and drugs.

Protein Name: FKBP Prolyl Isomerase 1B

Functions: Has the potential to contribute to the immunosuppressive and toxic effects of FK506 and rapamycin. PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides

The "FKBP1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FKBP1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

FKBP1C | FKBP2 | FKBP3 | FKBP4 | FKBP5 | FKBP6 | FKBP7 | FKBP8 | FKBP9 | FKBP9P1 | FKBPL | FKRP | FKSG29 | FKTN | FLACC1 | FLAD1 | FLCN | FLG | FLG-AS1 | FLG2 | FLI1 | FLII | FLJ12825 | FLJ13224 | FLJ16779 | FLJ20021 | FLJ20712 | FLJ25758 | FLJ30679 | FLJ31945 | FLJ32154 | FLJ32255 | FLJ33534 | FLJ36000 | FLJ37201 | FLJ37786 | FLJ38576 | FLJ39095 | FLJ40194 | FLJ42393 | FLJ42627 | FLJ42969 | FLJ43315 | FLJ44342 | FLJ44635 | FLJ45513 | FLJ46875 | FLNA | FLNB | FLNC | FLOT1 | FLOT2 | FLRT1 | FLRT2 | FLRT3 | FLT1 | FLT3 | FLT3LG | FLT4 | FLVCR1 | FLVCR1-DT | FLVCR2 | FLVCR2-AS1 | FLYWCH1 | FLYWCH2 | FMC1 | FMC1-LUC7L2 | FMN1 | FMN2 | FMNL1 | FMNL2 | FMNL3 | FMO1 | FMO2 | FMO3 | FMO4 | FMO5 | FMO6P | FMO9P | FMOD | FMR1 | FMR1-AS1 | FMR1NB | FN1 | FN3K | FN3KRP | FNBP1 | FNBP1L | FNBP1P1 | FNBP4 | FNDC1 | FNDC10 | FNDC11 | FNDC3A | FNDC3B | FNDC4 | FNDC5 | FNDC7 | FNDC8 | FNDC9